Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834767 | 0.80 | ADORA2A (0.62) | ADORA2BADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL1553929 | 0.79 | ADORA1 (0.61) | ADORA2BADORA2AADORA1ALDH1A1 | |
| SCHEMBL3840117 | 0.78 | CHUK (0.51) | ADORA2BADORA2AADORA1CHUKMAP4K4 | |
| SCHEMBL6765596 | 0.77 | ADORA1 (0.49) | ADORA2BADORA2AADORA1CHUKMAP4K4 | |
| SCHEMBL1553887 | 0.76 | ADORA2A (0.53) | ADORA2BADORA2AADORA1 | |
| SCHEMBL3835823 | 0.74 | ADORA2A (0.41) | ADORA2BADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL5189592 | 0.73 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ALDH1A1 | |
| SCHEMBL22172398 | 0.72 | MAP4K4 (0.52) | ADORA2BADORA2AADORA1CHUKMAP4K4 | |
| SCHEMBL6770039 | 0.71 | PIK3R1 (0.52) | ADORA2BADORA2AADORA1CHUKMAP4K4 | |
| SCHEMBL20600627 | 0.71 | ADORA2A (0.49) | ADORA2BADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | claimed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | claimed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | ADORA2B 2/4885ADORA2A 3/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.